Evaluation of dry eye parameters and meibomian gland function using the Lipiscan system in male androgenetic alopecia patients.

IF 1.7 4区医学 Q3 OPHTHALMOLOGY Clinical and Experimental Optometry Pub Date : 2025-01-26 DOI:10.1080/08164622.2025.2452275

Huriye Aybüke Koc, Hakan Koc

{"title":"Evaluation of dry eye parameters and meibomian gland function using the Lipiscan system in male androgenetic alopecia patients.","authors":"Huriye Aybüke Koc, Hakan Koc","doi":"10.1080/08164622.2025.2452275","DOIUrl":null,"url":null,"abstract":"Clinical relevance: The prevalence of male androgenetic alopecia is increasing worldwide. Evaluation of dry eye parameters and meibomian glands of male androgenetic alopecia patients may help to better understand the effect of this disease on dry eye and to provide appropriate treatment for these patients.Background: The aim of this work is to evaluate the relationship between male androgenetic alopecia, dry eye, and meibomian gland function.Method: A total of 80 eyes of 80 patients, 40 eyes of 40 patients diagnosed with male androgenetic alopecia, and 40 eyes of 40 healthy men were included. The presence of dry eye was evaluated with the Schirmer I test, invasive tear film break-up time (TBUT), Oxford scale scoring (cornea and conjunctiva staining), and the Ocular Surface Disease Index score. Evaluation of the eyelid meibomian glands was performed using the LipiScan System, and the descending meibomian glands for each eyelid were scored proportionally.Results: The average age of patients with androgenetic alopecia and the control group is 41.93 ± 6.65 and 40.75 ± 7.32 years, respectively (p = 0.413). The mean Schirmer I test score was statistically significantly lower in the androgenetic alopecia group (p = 0.001), and the mean Ocular Surface Disease Index score was significantly higher in the androgenetic alopecia group compared to the control group (p = 0.001). In the androgenetic alopecia group, mean TBUT was lower (p = 0.001) and mean Oxford scale score was higher (p = 0.009). Total, upper, and lower meibomian gland scores were statistically significantly higher in the androgenetic alopecia group (p = 0.001, p = 0.001, and p = 0.001, respectively).Conclusion: There may be an association between male androgenetic alopecia and dry eye and meibomian gland dysfunction. Male individuals with androgenetic alopecia should be closely followed for dry eye and meibomian gland dysfunction.","PeriodicalId":10214,"journal":{"name":"Clinical and Experimental Optometry","volume":" ","pages":"1-7"},"PeriodicalIF":1.7000,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Optometry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08164622.2025.2452275","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Clinical relevance: The prevalence of male androgenetic alopecia is increasing worldwide. Evaluation of dry eye parameters and meibomian glands of male androgenetic alopecia patients may help to better understand the effect of this disease on dry eye and to provide appropriate treatment for these patients.

Background: The aim of this work is to evaluate the relationship between male androgenetic alopecia, dry eye, and meibomian gland function.

Method: A total of 80 eyes of 80 patients, 40 eyes of 40 patients diagnosed with male androgenetic alopecia, and 40 eyes of 40 healthy men were included. The presence of dry eye was evaluated with the Schirmer I test, invasive tear film break-up time (TBUT), Oxford scale scoring (cornea and conjunctiva staining), and the Ocular Surface Disease Index score. Evaluation of the eyelid meibomian glands was performed using the LipiScan System, and the descending meibomian glands for each eyelid were scored proportionally.

Results: The average age of patients with androgenetic alopecia and the control group is 41.93 ± 6.65 and 40.75 ± 7.32 years, respectively (p = 0.413). The mean Schirmer I test score was statistically significantly lower in the androgenetic alopecia group (p = 0.001), and the mean Ocular Surface Disease Index score was significantly higher in the androgenetic alopecia group compared to the control group (p = 0.001). In the androgenetic alopecia group, mean TBUT was lower (p = 0.001) and mean Oxford scale score was higher (p = 0.009). Total, upper, and lower meibomian gland scores were statistically significantly higher in the androgenetic alopecia group (p = 0.001, p = 0.001, and p = 0.001, respectively).

Conclusion: There may be an association between male androgenetic alopecia and dry eye and meibomian gland dysfunction. Male individuals with androgenetic alopecia should be closely followed for dry eye and meibomian gland dysfunction.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

临床意义：全球男性雄激素性脱发的发病率正在上升。对男性雄激素性脱发患者的干眼参数和睑板腺进行评估有助于更好地了解这种疾病对干眼的影响，并为这些患者提供适当的治疗：本研究旨在评估男性雄激素性脱发、干眼症和睑板腺功能之间的关系：方法：共纳入 80 名患者的 80 只眼睛，其中 40 名患者被诊断为男性雄激素性脱发，40 名患者被诊断为男性雄激素性脱发，40 名健康男性被诊断为男性雄激素性脱发。通过施尔默 I 试验、侵入性泪膜破裂时间（TBUT）、牛津量表评分（角膜和结膜染色）和眼表疾病指数评分来评估是否存在干眼症。使用 LipiScan 系统对眼睑睑板腺进行评估，按比例对每个眼睑的睑板腺进行评分：雄激素性脱发患者和对照组的平均年龄分别为（41.93 ± 6.65）岁和（40.75 ± 7.32）岁（P = 0.413）。在统计学上，雄激素性脱发组的平均 Schirmer I 测试得分明显低于对照组（p = 0.001），雄激素性脱发组的平均眼表疾病指数得分明显高于对照组（p = 0.001）。雄激素性脱发组的平均 TBUT 值较低 (p = 0.001)，平均牛津量表评分较高 (p = 0.009)。雄激素性脱发组的睑板腺总分、上分和下分在统计学上明显更高（分别为 p = 0.001、p = 0.001 和 p = 0.001）：结论：男性雄激素性脱发与干眼症和睑板腺功能障碍之间可能存在关联。男性雄激素性脱发患者应密切关注干眼症和睑板腺功能障碍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical and Experimental Optometry 医学-眼科学

CiteScore

4.10

自引率

5.30%

发文量

132

审稿时长

6-12 weeks

期刊介绍： Clinical and Experimental Optometry is a peer reviewed journal listed by ISI and abstracted by PubMed, Web of Science, Scopus, Science Citation Index and Current Contents. It publishes original research papers and reviews in clinical optometry and vision science. Debate and discussion of controversial scientific and clinical issues is encouraged and letters to the Editor and short communications expressing points of view on matters within the Journal''s areas of interest are welcome. The Journal is published six times annually.